Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buprenorphine gum vs sublingual tablet for detoxification
IRCT20120215009014N607Phase 3Completed
- Sponsor
- Hamadan University of Medical Sciences
- Start
- Jun 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of buprenorphine in opioid use disorder (OUD) and opioid withdrawal (2 arms), sponsored by Hamadan University of Medical Sciences. Started Jun 2026; status: completed.
02
Drugs
buprenorphine
03
Conditions
opioid use disorder (OUD)opioid withdrawal
Beyond the preview
Go deeper on IRCT20120215009014N607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20120215009014N607.